AbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance

MT Newswires Live

03 Apr

AbbVie-6.38%

AbbVie (ABBV) said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.

Analysts polled by Factset, on average, are expecting $2.51.

The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.

Analysts are modeling for a $12.30 profit.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524114602"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524114602\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524114602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-04 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524114602","market":"sh","top_or_hot":-1,"title":"AbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance","media":"MT Newswires Live","content":"<html><body><p> AbbVie (ABBV) said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.</p><p>Analysts polled by Factset, on average, are expecting $2.51.</p><p>The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.</p><p>Analysts are modeling for a $12.30 profit.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-04 05:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AbbVie (ABBV) said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.</p><p>Analysts polled by Factset, on average, are expecting $2.51.</p><p>The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.</p><p>Analysts are modeling for a $12.30 profit.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524114602","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524114602","pubTimestamp":1743715810,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbbVie  said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.Analysts polled by Factset, on average, are expecting $2.51.The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.Analysts are modeling for a $12.30 profit.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"艾伯维发布第一季度调整后盈利前景，下调全年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1},"content_text":"AbbVie (ABBV) said Thursday it expects to report Q1 adjusted earnings of $2.34 to $2.38 per diluted share, reflecting an unfavorable impact of $0.13 per share from $248 million in acquired in-process research and development expenses and milestone payments.Analysts polled by Factset, on average, are expecting $2.51.The company said it now expects full-year 2025 adjusted earnings of $11.99 to $12.19 per share, down from its prior guidance of $12.12 to $12.32 issued in January.Analysts are modeling for a $12.30 profit.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.